Proteomic discoveries in dementia and kidney disease: Harnessing 135 million measurements and 30 years of follow-up
The NIH-funded Atherosclerosis Risk in Communities (ARIC) Study, which began in 1987, is a treasure trove of longitudinal, clinical data for biomarker discovery. In this webinar, Josef Coresh will discuss how his team and collaborators have mined that data by connecting ARIC’s rigorous epidemiologic cohorts with breakthrough proteomic quantification enabled by the SomaScan® Assay.
Using the SomaScan Assay, ~5,000 proteins were measured on frozen plasma from three visits conducted during 1990-1992 (n>10,000), 1993-1995 (N>12,000) and 2011-2013 (N>5,000). Following quality control verification of high precision, data were cleaned and shared with approximately 100 scientists working with ARIC data, who developed 64 approved manuscript proposals (3 published thus far, 13 forthcoming).
Methods for discovery, internal, and external validation were developed with success for chronic kidney disease and dementia. Discoveries highlighted specific prognostic target proteins (e.g. SVEP for dementia and TNFsR1 and LMAN2 for CKD) and pathways for each disease with Mendelian Randomization evidence of causation supporting some as useful targets for intervention.
Josef Coresh, M.D., Ph.D
Professor of Epidemiology, Medicine and Biostatistics
Dr. Joe Coresh is the George W. Comstock Professor of Epidemiology, Biostatistics and Medicine at The Johns Hopkins University Bloomberg School of Public Health*, where he leads the ARIC study – a cohort of 16,000 participants followed since 1987 – and co-leads the CKD Prognosis Consortium (CKD-PC), which includes over 80 cohorts and >10 million participants from 40+ countries.
Dr. Coresh’s research portfolio is diverse following the blood vessels from the heart to the kidney and the brain with grants of over $5M/year focused on big data and molecular studies. An international expert in kidney and cardiovascular disease epidemiology, Dr. Coresh has co-authored over 800 research articles cited over 100,000 times, was vice-chair of the 2002 NKF guideline whose definition of kidney disease is now used globally, and co-published the equations used for estimating kidney function globally.
Each year since 2014 Dr. Coresh has been recognized as being among the top 1% of researchers in Clinical Medicine globally (by article citations). Among other awards, he received the top scientific and patient impact awards of the United States National Kidney Foundation (NKF Eknoyan and Hume awards) and American Society of Nephrology (ASN Scribner award).
*Nothing contained herein shall be construed to imply any support or endorsement of SomaLogic, Inc. by The Johns Hopkins University.
WebinarUtilizing proteomic strategies to uncover novel biomarkers and mechanisms in heart failure
Plasma proteomics is a powerful approach for discovering novel protein biomarkers of drug toxicity in various disease contexts. One such biomarker in cardiovascular disease is apolipoprotein M (ApoM), which plays a crucial role in lipid metabolism and transport and is known to have both anti-inflammatory and cardioprotective effects in the body. Studying ApoM using proteomics requires various approaches to understand its expression, modifications, interactions, and functions in the proteome.
WebinarUsing plasma proteomics to understand Alzheimer’s and other brain diseases
Dr. Walker discusses how he integrates proteomic, genetic, brain imaging and cerebral spinal fluid biomarkers from initially cognitively normal individuals who later develop dementia, in order to discover novel blood-based biomarkers and mechanistically relevant proteins for therapeutic target prioritization.
WebinarProteomics for precision neuroscience: The power of protein analysis
This webcast highlights how academic, industry and government researchers are directly measuring protein abundance and function via multiplex proteomics to build more detailed characterizations of the biological systems underlying neurodegenerative diseases.